

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/568, 47/44	A1	(11) International Publication Number: WO 00/59512 (43) International Publication Date: 12 October 2000 (12.10.00)
(21) International Application Number: PCT/EP00/02677 (22) International Filing Date: 27 March 2000 (27.03.00) (30) Priority Data: 99302581.6 1 April 1999 (01.04.99) EP (71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): NIJS DE, Henrik [NL/NL]; Hermelijnedreef 27, NL-5343 XC OSS (NL). CHANDLER, Susan [GB/GB]; 43 Herd Street, Marlborough, Wiltshire (GB). PERRY, Elizabeth, Anne [GB/GB]; 1 Copper Beeches, Swindon, Highworth SN6 7BJ (GB). FERDINANDO, Josephine, Joan, Christine [GB/GB]; 16 Lytham Close, Monkton Park, Chippenham SN15 3XW (GB). (74) Agent: KRAAK, Hajo; P.O. Box 20, NL-5340 BH Oss (NL).		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: FORMULATION COMPRISING TESTOSTERONE UNDECANOATE AND CASTOR OIL		
(57) Abstract <p>Disclosed is a pharmaceutical formulation in the form of a capsule for oral administration comprising testosterone undecanoate as an active ingredient dissolved in a pharmaceutically acceptable liquid carrier, characterised in that the liquid carrier comprises at least 50 % by weight of castor oil. The choice of castor oil as the liquid carrier, in conjunction with the choice of testosterone undecanoate as the androgen, makes for a solution which can comprise about 200–250 mg/ml of TU. This is a novel achievement for any orally administerable solution of testosterone. The solution may also contain a lipophilic surfactant such as lauroglycol.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

FORMULATION COMPRISING TESTOSTERON UNDECANOATE AND CASTOR OIL

5 The invention is in the field of androgen formulations for oral administration. Such formulations have acquired new attention in view of the development of preparations for male contraception and male HRT (hormone replacement therapy). In both cases the androgen may particularly be used as a replacement for endogenic testosterone. Thus, e.g., in male HRT, androgen is administered in order to relieve the undesired effects of the (partial) androgen-deficiency which may result of age. Androgens can also be used in the female, e.g. as androgen replacement therapy in postmenopausal women.

15 Oral preparations of androgens are rare, the only oral natural testosterone product available on the market being a solution of testosterone undecanoate (TU) in oleic acid. This product, which is known in various countries under various tradenames, e.g. Andriol® or Restandol®, is a soft-gelatine capsule formulation containing 40 mg of TU dissolved in oleic acid. To achieve and maintain acceptable testosterone levels in the blood, 3-4 such capsules should be administered daily. A regimen involving such a large number of separate administrations is not very suitable for the practical use of TU as an acceptable HRT product, let alone that it would be accepted this way in contraception.

20 The invention seeks to solve the problem of providing an orally active androgen formulation which is well absorbed in the human body. Particularly, the invention seeks to provide a formulation of TU which has a higher strength than the known TU formulation referred to above.

25 To meet these and other objectives, the invention provides a pharmaceutical formulation in the form of a capsule for oral administration comprising testosterone undecanoate as an active ingredient dissolved in a pharmaceutically acceptable liquid carrier, wherein the liquid carrier is castor oil. Although, in one embodiment, castor oil can be the sole liquid carrier, it is also possible to combine castor oil with other liquid carriers. It is desired,

30

however, that castor oil is the main component of the liquid carrier, i.e. it makes up more than 50% by weight of said carrier.

The choice of castor oil as the liquid carrier, in conjunction with the choice of testosterone undecanoate as the androgen, makes for a solution which can comprise about 200-250 mg of TU per ml. This amounts to approximately 127 to 137 mg of testosterone per ml. This is a novel achievement for any orally administerable solution of testosterone in any form. The invention, in one aspect, therefore includes a pharmaceutical formulation in the form of a capsule for oral administration comprising testosterone undecanoate as the active ingredient dissolved in a pharmaceutically acceptable liquid carrier in a concentration of 200-250 mg/ml.

It is noted that Exp.Clin.Endocrinol.Diabetis 105 Suppl.1,21,1997 and Eur. J. Endocrinol.123:514-9 (195) make mention of an injectable solution of 250 mg/ml of TU in castor oil. This, however, does not at all lead the way to the possibility of achieving oral administration of a similar level of TU. These are separate fields of pharmaceutical formulation, and, moreover, an injection directly into the muscle cannot be used as a model for administration via the oral route. In addition, it is all the more surprising that notably castor oil is a suitable carrier for this type of administration, since its normal capacity is that of a laxative. This, of course, is a use completely opposite to that underlying the present invention, wherein the goal is to make something (in this case TU) enter and be absorbed into the human body rather than make it leave the body by inducing excretion. Hence it is fully unexpected that castor oil turns out to be a highly suitable carrier for the oral administration of TU, which is absorbed well.

25

The invention also includes the use of testosterone undecanoate for the manufacture of a medicine in the form of an oral solution, wherein testosterone undecanoate is dissolved in a pharmaceutically acceptable liquid carrier, characterised in that the liquid carrier comprises at least 50% by weight of castor oil. In yet another aspect, the invention is a method of treatment comprising the administration of testosterone undecanoate to a human male or

30

female in need of androgen supplementation, characterised in that the testosterone undecanoate is administered orally in the form of a solution in a carrier, the latter comprising at least 50% by weight of castor oil. In order to achieve optimal administration of TU, the capsules should be taken preferably during or just after a meal.

5

In all of the above aspects, it is preferred that, in addition to the TU and the castor oil, the capsules include additives such as disclosed in WO 97/40823 and WO 95/24893. It is most preferred to base the formulation on a particular combination of castor oil and a lipophilic surfactant, as such a combination provides a liquid vehicle for dissolving TU resulting in the most stable formulations which best promote lymphatic absorption. Thus the preferred formulation is one in which TU is dissolved in a liquid vehicle which comprises of from 50 to 70% by weight of castor oil, and from 30 to 50% by weight of a lipophilic surfactant having an HLB <10, and, optionally, from 0 to 20% by weight of a hydrophilic surfactant, wherein the liquid vehicle is substantially free from the free fatty acid and contains less than 10% by weight of ethanol. Suitable lipophilic surfactants having an HLB <10 are known to the person skilled in the art. These include mono- and/or diglycerides of fatty acids as well as mono- and/or diglycerides of fatty acids in which the remaining free OH groups of glycerol can be esterified, such as the acetic, succinic, lactic, citric and/or tartaric esters thereof; propylene glycol mono- and/or di-esters of fatty acids; ethoxylates of castor oil or of hydrogenated castor oil (low ethoxylate content, HLB < 10); acid and ester ethoxylates formed by reacting ethylene oxide with fatty acids or glycerol esters of fatty acids; sorbitan esters of fatty acids; unsaturated polyglycolised glycerides (if HLB < 10); alcohol ethoxylates (if HLB <10); polyoxyethylene-polyoxypropylene co-polymers and block copolymers (if HLB < 10). The lipophilic surfactant is preferably used in an amount in the range of from 35 to 45% by weight of the liquid vehicle. A preferred lipophilic surfactant is lauroglycol (propylene glycol monolaurate). The optional hydrophilic surfactants are also known to the person skilled in the art. Any pharmaceutically acceptable hydrophilic surfactant (i.e., having an HLB value greater than 10) may be used in the present invention. The formulations may contain minor amounts of other additives, e.g., anti-oxidants, such as

d- α -tocopherol, BHA, BHT; co-solvents such as ethanol and Transcutol (diethylene glycol monoethylether), plasticisers, such as propylene glycol, etc.

The formulations of the invention may readily be prepared by known methods, e.g. as
5 described in WO 95/24893. The capsules encapsulating the formulations can be made by
known techniques. Gelatine softgels, as with Andriol®, are preferred, but the wall of the
capsule may be made from any pharmaceutically acceptable softshell or hardshell material.
Methods of softgel encapsulation are disclosed in Theory and Practice of Industrial
Pharmacy - Lachman & Leibermann, 2nd Edition, published by Henry Kimpton Publishers,
10 London. Methods of liquid-fill hardshell encapsulation are disclosed in Hardcapsules -
Development and Technology - Edited by K. Ridgeway, published by Pharmaceutical Press
1987.

15 The invention will be further illustrated hereinafter with reference to the Example.

EXAMPLE

The following ingredients are added to a suitable mixer (Unimix) and heated to 40°C:

20	Castor oil BP	53 parts by weight
	Lauroglycol FCC	35 parts by weight
	Testosteron undecanoate	12 parts by weight

After complete dissolution the resulting solution is filled into soft gelatine capsules of 330
ml using standard equipment. A stable formulation is obtained, from which TU is absorbed
25 well orally.

Claims:

1. A pharmaceutical formulation in the form of a capsule for oral administration comprising testosterone undecanoate as an active ingredient dissolved in a
5 pharmaceutically acceptable liquid carrier, characterised in that the liquid carrier comprises at least 50% by weight of castor oil.
2. A pharmaceutical formulation according to claim 1, characterised in that the sole liquid
10 carrier is castor oil.
3. A pharmaceutical formulation according to claim 1, characterised in that the liquid carrier further comprises from 30 to 50% by weight of a lipophilic surfactant having an HLB value below 10.
- 15 4. A pharmaceutical formulation according to claim 3, characterised in that the lipophilic surfactant is lauroglycol.
5. A pharmaceutical formulation according to any one of the preceding claims, characterised in that testosterone undecanoate is dissolved in a concentration of 200-250
20 mg/ml.
6. The use of testosterone undecanoate for the manufacture of a medicine in the form of an oral solution, wherein testosterone undecanoate is dissolved in a pharmaceutically acceptable liquid carrier, characterised in that the liquid carrier comprises at least 50%
25 by weight of castor oil.
7. A method of treatment comprising the administration of testosterone undecanoate to a human male in need of androgen supplementation, characterised in that the testosterone undecanoate is administered orally in the form of a solution in a carrier, the latter
30 comprising at least 50% by weight of castor oil.

8. A pharmaceutical formulation in the form of a capsule for oral administration comprising testosterone undecanoate as the active ingredient dissolved in a pharmaceutically acceptable liquid carrier in a concentration of 200-250 mg/ml.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/02677

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/568 A61K47/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 40823 A (SCHERER LTD R P ; CHANDLER SUSAN GERRARD (GB); FERDINANDO JOSEPHINE) 6 November 1997 (1997-11-06)	8
Y	examples 21-38 --- -/--	1-8



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 June 2000

Date of mailing of the international search report

06/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

Inter national Application No
PCT/EP 00/02677

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEMICAL ABSTRACTS, vol. 107, no. 13, 28 September 1987 (1987-09-28) Columbus, Ohio, US; DAVIDSON D W ET AL: "Increasing circulating androgens with oral testosterone undecanoate in eugonadal men" page 91; XP002082921 abstract & DAVIDSON D W ET AL: "Increasing circulating androgens with oral testosterone undecanoate in eugonadal men" J STEROID BIOCHEM, vol. 26, no. 6, 1987, pages 713-715, ENGLAND ---	1-8
Y	WO 95 12383 A (ZHEJIANG MEDICAL UNIVERSITY ;ZHEJIANG XIANJU PHARMACEUTICAL (CN);) 11 May 1995 (1995-05-11) abstract ---	1-8
Y	WO 98 36770 A (DZIEGLEWSKA HANNA EVA ;CORTENDO AB (SE); MAARIN PER (SE)) 27 August 1998 (1998-08-27) page 10, line 11-21 -----	1-8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/02677

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9740823 A	06-11-1997	AU 2707497 A EP 0904064 A	19-11-1997 31-03-1999
WO 9512383 A	11-05-1995	CN 1102095 A AU 7988994 A	03-05-1995 23-05-1995
WO 9836770 A	27-08-1998	AU 6302398 A CN 1248170 T NO 994053 A	09-09-1998 22-03-2000 24-09-1999